



Do randomised controlled trials relevant to pharmacy meet 








1. Master of Pharmacy Student, Division of Pharmacy, University of Western Australia, 
Australia 
2. Assistant Professor, Division of Pharmacy, University of Western Australia, Australia. 
https://orcid.org/0000-0002-7302-6303  
3. Professor, Head of School, Allied Health, University of Western Australia, Australia 
4. Emeritus Professor Primary Care, Institute of Applied Health Sciences, University of 
Aberdeen, Scotland UK 





Acknowledgements: The study was conceived by CB, all authors contributed to the design, 3 
reviewed results and commented on successive drafts of the paper and approved the final 4 
version. AR undertook all the searches, data extraction and analyses, and prepared the first draft 5 
of the manuscript. The project was undertaken by AR as her Master of Pharmacy research 6 
project during a placement at the University of Aberdeen Scotland under the local supervision 7 
of Christine Bond.  Special thanks to Moira Cruickshank, from the Health Services Research 8 
Unit at the University of Aberdeen for assistance in the construction of the search strategy.  9 
 10 
 11 
ABSTRACT  12 
Background: Evidence-based pharmacy practice requires a dependable evidence base. 13 
Randomised controlled trials (RCTs) are the gold standard of high quality primary research, 14 
and tools exist to assist researchers in conducting and reporting high quality RCTs. This review 15 
aimed to explore whether RCTs relevant to pharmacy are conducted and reported in line with 16 
Cochrane risk of bias and CONSORT standards respectively. 17 
Methods: A Medline search identified potential papers. After screening of titles, abstracts and 18 
full texts, the 50 most recent papers were reviewed and assessment of bias according to 19 
Cochrane domains and compliance with CONSORT checklist items was recorded. Each 20 
domain of the Cochrane tool, CONSORT checklist item, and each article was given a 21 
percentage score, reported as median and interquartile range (IQR). Correlation between quality 22 
of conduct, quality of reporting, country of origin, and journal impact factor was conducted 23 
using the R2 statistic.  24 
Results: The median domain score for risk of bias by paper according to the Cochrane risk of 25 
bias tool was 53.0% (IQR 38.5-68.5), while the median compliance score by paper for the 26 
CONSORT checklist was 64.0% (IQR 36.0%-94.0%).  The median Cochrane domain, and 27 




59.5% (IQR 52.0%-70.3%). The highest risk of bias was associated with allocation 29 
concealment and blinding, and the least well reported items were randomisation details, 30 
sequence generation and allocation concealment. A positive relationship between conduct and 31 
reporting of RCTs was found (R² = 0.75), while no correlation was found between quality of 32 
conduct or quality of reporting and journal impact factor, correlation coefficients (R²=0.06 and 33 
R²=0.05 respectively).  34 
Conclusion(s): This review identified that issues related to randomisation and blinding are 35 
often  inadequately conducted or  not comprehensively reported   by researchers conducting 36 
pharmacy relevant RCTs, providing useful information for education and future research.  37 
Keywords:   RCT, Systematic Review, Pharmaceutical Care, Other 38 
INTRODUCTION 39 
Evidence-based pharmacy practice requires a dependable evidence base.1 As the gold standard 40 
of high quality primary research,2,3 the evidence from randomised controlled trials (RCTs)  is 41 
the usual basis for meta-analysis and systematic review, which informs policy and practice.4,5 42 
However, when evidence from high quality RCTs is not available, decisions are based on expert 43 
consensus.3,6  44 
 45 
In the global context, pharmacists have been acknowledged by the public as accessible and 46 
trusted health professionals,7,8 and they are therefore uniquely placed to provide health related 47 
interventions to patients. However, systematic reviews of pharmacist led interventions often 48 
grade the quality of the research evidence base as low.9-11 49 
 50 
For evidence obtained from RCTs to be graded as high, the studies must be conducted robustly, 51 
and reported in a clear and transparent manner.2,12 There are many tools available to assist 52 




widely acknowledged checklist, which, if followed, facilitates the reporting of transparent and 54 
high quality RCT publications.2  In order to meet the requirements of the CONSORT checklist 55 
satisfactorily, the planning and conduct of the study has to have included the topic of each 56 
checklist item. However, the CONSORT checklist per se is not intended for use in assessment 57 
of quality of RCT methodology.2  58 
 59 
When using evidence from RCTs to inform practice change, it is important to recognise the 60 
limitations of the original research which might affect the validity of the findings. For example, 61 
poorly conducted studies often lead to results which favour the intervention. The Cochrane 62 
collaboration’s tool for assessing risk of bias in randomised trials13 (the Cochrane risk of bias 63 
tool) comprises six domains against which an RCT is judged as having a high, low or unclear 64 
risk of bias. Therefore, assessing any study against a combination of the Cochrane risk of bias 65 
tool and the CONSORT reporting checklist highlights potential areas of weakness and allows 66 
the study findings to be interpreted in the context of any caveats.  It is considered likely that 67 
studies which have been well reported, are developed with current standards of good research 68 
practice in mind, and therefore these studies are likely to have equivalently lower biases when 69 
assessed against the Cochrane tool. Finally, if research findings are to influence practice and 70 
policy, they need to be in the public domain, and authors are dependent on acceptance by 71 
academic journals for this to occur. It is therefore imperative that for journals to accept papers 72 
they prioritise studies conducted in an appropriate manner, and that the most highly regarded, 73 
higher impact factor journals only accept stronger papers.    74 
 75 
This review aimed to explore whether RCTs relevant to pharmacy are conducted and reported 76 
in line with Cochrane and CONSORT standards respectively. The objectives of this review of 77 




o to describe the quality of conduct using the Cochrane tool, 79 
o to describe the quality of reporting using the CONSORT checklist, 80 
o to identify if there is a relationship between quality of conduct and quality of reporting 81 
in RCTs, and 82 
o to explore the relationship between journal impact factor, quality of conduct and quality 83 
of reporting of RCTs. 84 
 85 
METHODS 86 
This review is reported following relevant items of the Preferred Reporting Items for Systematic 87 
Reviews and Meta-Analyses (The PRISMA Statement).14   88 
 89 
Eligibility criteria 90 
Eligible papers included those: reporting the results of an RCT relevant to pharmacy (i.e. studies 91 
involving interventions implemented by a pharmacist or pharmacy technician, or interventions 92 
occurring in any pharmacy setting). Comparators included usual care or non-pharmacy 93 
interventions, and outcomes were any measure of change. Inclusion and exclusion criteria are 94 
listed in Table 1.  95 
 96 
Information sources 97 
The Medline database was used to identify eligible papers for inclusion in analysis. A single 98 
database was used due to time constraints. 99 
 100 
Search 101 
The Cochrane highly sensitive search strategy for identifying RCTs in Medline15 was used to 102 




used, as shown in Table 2. The filter “English language only” was applied to the search. The 104 
search was conducted on the 30th of November 2017.  105 
 106 
Sample size 107 
The target sample was the most recent 50 eligible papers identified by Medline. This sample 108 
size was selected a priori for the following reasons.  Firstly, only the most recently published 109 
papers would allow the current quality of conduct and reporting of pharmacy relevant RCTs to 110 
be assessed. This recognised that standards in conducting and reporting RCTs across the wider 111 
discipline of health services research are continually improving.  Secondly, it was decided by 112 
consensus that 50 papers would balance being a large enough sample to provide generalisable 113 
results, yet, not too large that the data extraction could not be performed thoroughly by a single 114 





Data collection process 120 
The most recent 200 papers identified by the Medline search were screened to identify eligible 121 
papers. This process was chosen with the intention of screening a further 200 papers, if 50 122 
eligible papers were not identified from the most recent 200 papers.  123 
 124 
The most recent 50 eligible papers were screened by title and duplicate papers were removed. 125 
Inclusion and exclusion criteria were applied during title screening and remaining papers were 126 
screened by abstract against the eligibility criteria. Where there was uncertainty about 127 




by consensus. If, following full text evaluation, a paper was excluded due to ineligibility, the 129 
next most recent eligible paper was included.   130 
 131 
Data items 132 
The 50 eligible papers were reviewed and data extracted by one researcher (AR) to assess the 133 
risk of bias and identify compliance with best practice reporting standards for RCTs using the 134 
Cochrane risk of bias and CONSORT tools respectively. Each paper was read by the researcher 135 
and received a coded numerical value denoting its risk of bias in each of the domains of the 136 
Cochrane risk of bias tool (1= low risk of bias, 2= high risk of bias, 3= unclear risk of bias). 137 
Each paper additionally received a coded numerical value denoting its compliance with each 138 
item of the CONSORT checklist (1= yes, 2= no, 3= unclear, 4= not applicable, 5= partially 139 
complete). As a quality assurance measure of the validity of the data extraction a second 140 
researcher (DP) independently extracted data and coded a random sample of ten papers (20%). 141 
 142 
A data matrix was assembled in Microsoft Excel 2016 using the domains of the Cochrane risk 143 
of bias tool and the items of the CONSORT checklist. Each researcher independently entered  144 
data to their version of the matrix   at the time of full text evaluation. Supporting information 145 
found along with each tool2,13 was used to assist the researcher in assigning codes to the papers. 146 
Additionally, publication and study information were recorded, including a summary of the 147 
evidence from the paper, journal and year of publication, country of origin and authors and their 148 
respective institutions. For the sample of ten papers where there was duplicate extraction, 149 
matrices were compared and a consensus agreed if needed.  150 
 151 




To enable comparison between papers based on risk of bias and quality of reporting, each paper 153 
was given a score. The Cochrane risk of bias score was the percentage of the domains classified 154 
as “low risk of bias”.  The CONSORT score was the percentage of checklist items which were 155 
classified as “yes”. Adjusted CONSORT scores were calculated for each paper by removing 156 
the “not applicable” responses from the denominator prior to calculating the percentage of “yes” 157 
responses. There was no need to adjust Cochrane risk of bias scores as there was no numerical 158 
code denoting “not applicable”. 159 
 160 
Additionally, each domain of the Cochrane risk of bias tool and each item of the CONSORT 161 
checklist were given a percentage score based on the number of papers which received a “low 162 
risk of bias” or “yes” code for that domain or item divided by the total number of papers. 163 
Adjusted CONSORT scores were calculated by determining the number of “not applicable” 164 
responses for each item, and removing these from the denominator before calculating the 165 
percentage of “yes” responses. This allowed identification of those items least well conducted 166 
or reported.  167 
 168 
Analysis and synthesis of results 169 
Analysis of results was completed in two parts. Firstly, each domain of the Cochrane risk of 170 
bias tool and item of the CONSORT checklist were assessed for frequency of each possible 171 
coded response. Domains of the tool and items of the checklist were ranked based on the 172 
frequency of “low risk of bias” and “yes” responses to determine the highest to lowest scoring 173 
areas of each tool, based on the percentage of these responses. If the data were normally 174 
distributed, mean +/- standard deviation (SD) was used to describe the data, while if the data 175 
were not normally distributed the median and interquartile range (IQR) were used. The median 176 




CONSORT were calculated to facilitate interpretation of how well domains and items of the 178 
tools were completed.  179 
 180 
Secondly, papers were ranked based on their individual Cochrane risk of bias and CONSORT 181 
scores. The median and IQR or mean +/- SD of the papers’ Cochrane risk of bias and 182 
CONSORT percentage scores were calculated to enable interpretation of the spread of the data. 183 
A scatter plot was created by pairing each individual paper’s Cochrane risk of bias score with 184 
its CONSORT score, to identify if there was correlation between quality of conduct with low 185 
risk of bias and reporting. A second scatter plot was created by pairing each individual paper’s 186 
adjusted CONSORT risk of bias score with its Cochrane score.  187 
 188 
 189 
The papers were also classified by the journal in which they were published. The median 190 
percentage scores and IQR or mean +/- SD for each journal was calculated to determine the 191 
spread of the data and facilitate interpretation. The median or mean score of each journal (for 192 
Cochrane risk of bias, CONSORT and adjusted CONSORT) was plotted against the journal’s 193 
current impact factor to explore any correlations. All data analysis was completed on Microsoft 194 
Excel 2016 for Macintosh.  195 
 196 
RESULTS 197 
Papers included in analysis 198 
The Medline search identified 1517 papers. The most recent 200 papers were screened by title; 199 
after removing duplicates (50) and those ineligible (27), 123 remained.  A further 66 papers 200 
were excluded following the abstract screening, leaving 57 eligible papers for data extraction 201 
(Figure 1).  Two papers from the most recent 50 were ineligible and were replaced by the next 202 




For the 20% random sample of papers that had independent duplicate data extraction consensus 204 
was reached for all items. .  205 
 206 
Overview of papers 207 
The largest number of papers was from North America (n=20), followed by Asia and Europe 208 
(both n=12), Australasia (n=4), and South America and Africa (both n=1). The papers covered 209 
a range of clinical (n=25), medication management/use (n=17), public health (n=6) and 210 
continuing professional development (CPD) (n=2) topics (Table 3).  A summary of the papers 211 
can be found in Supplemental material 1. 212 
 213 
Quality of reporting and risk of bias  214 
The papers’ median domain score for risk of bias according to the Cochrane risk of bias tool 215 
was 53.0% (IQR 38.5-68.5). There was a high risk of bias due to inadequate allocation 216 
concealment and blinding (66% and 56% of papers respectively).  Conversely, 70% of papers 217 
were assessed as a low risk of bias score for selective outcome reporting. For other sources of 218 
bias, 38% of papers were assessed as high risk or unclear risk, and 24% as low risk (Table 4).   219 
 220 
The median level of compliance by paper with the items of the CONSORT reporting checklist 221 
for RCTs was 64.0% (IQR 36.0%-94.0%). All papers met item 2a (scientific background and 222 
rationale), and none met item 7b (when applicable, explanation of any interim analyses and 223 
stopping guidelines).  After adjusting for ‘not applicable’ items (5 items had >80% of papers 224 
coded as ‘not applicable’), fifteen checklist items were completed by at least 90% of papers 225 
(2a, 2b, 3b, 4a, 4b, 5, 6a, 6b, 11b, 12a, 15, 16, 20, 22 and 25) and six for less than 50% of papers 226 




scores for each item of the CONSORT checklist are displayed in Table 5.  Items least well 228 
reported were related to randomisation and blinding (8a,8b,9,10). 229 
 230 
Quality of reporting and risk of bias of individual papers  231 
The median Cochrane risk of bias score by individual paper was 50.0% (IQR 33.3-66.7). Only 232 
one paper16 met all criteria of the Cochrane tool and two papers17,41 did not meet any. The 233 
median CONSORT score was 59.5% (IQR 52.0%-70.3%) with three papers18-20 meeting 83.8% 234 
of the criteria and one meeting only 29.7% 21. The median adjusted CONSORT score was 235 
72.4% (IQR 61.8%-83.9%), with the highest score of 96.9% achieved by one paper,20 and the 236 
lowest (35.5%) by one paper21  (see Supplemental Material 2 and Supplemental Material 3).  237 
 238 
Additional analyses 239 
There was a correlation between Cochrane and CONSORT scores, (y = 1.5165x - 39.197, R² = 240 
0.72), as shown in Figure 2. The same correlation was observed using adjusted CONSORT 241 
scores (y = 1.4292x - 49.735, R² = 0.75). 242 
 243 
Considering only those continents with more than one paper included in analysis, Australasia 244 
(n=4) was the continent with the highest median Cochrane, CONSORT and adjusted 245 
CONSORT scores, of 75.0%, (IQR 62.5-85.4%), 68.9% (IQR 65.5-72.9%) and 82.3% (IQR 246 
78.8-86.3%) respectively, and North America (n=20) was the continent with the lowest 247 
Cochrane, CONSORT and adjusted CONSORT scores, of 45.8% (IQR 33.3-66.7%), 56.7% 248 
(IQR 51.4-70.9%) and 66.2% (IQR 60.5-82.3%) respectively. The median percentage scores 249 
classified by continent are displayed in Supplemental material 5.  250 
 251 
There was no correlation between Cochrane scores and journal impact factor or CONSORT 252 




respectively. Additionally, there was no correlation between journals’ adjusted median 254 
CONSORT score and journal impact factor (R2=0.04).  255 
 256 
Supplemental material 4 summarises journal impact factor with median Cochrane, CONSORT, 257 
and adjusted CONSORT scores. The journal with the highest impact factor, The Journal of the 258 
American College of Cardiology (impact factor 19.9), had Cochrane, CONSORT and adjusted 259 
CONSORT scores of 75.0%, 72.9%, and 81.8% respectively. There were several journals with 260 
an impact factor of 0 (n=5). Of these, BMC Public Health was the journal with the most 261 
consistent high results with median Cochrane, CONSORT and adjusted CONSORT scores of 262 
91.7%, 83.8% and 93.9% respectively.  263 
 264 
DISCUSSION 265 
This review showed that of 50 RCTs relevant to pharmacy, only one met all the quality 266 
standards in every domain of the Cochrane risk of bias tool, and approximately one quarter 267 
met only two out of six domains. The criterion for low risk of bias in allocation concealment 268 
was met by the fewest number of papers, with only a third complying, and under half 269 
complied with the criterion for blinding of participants, personnel and outcome assessors. 270 
Conversely, selective outcome reporting, i.e. reporting all outcomes originally specified, was 271 
the domain for which most papers were assessed as meeting the criterion. Similarly, no paper 272 
reported on all the items required by the CONSORT checklist, although one reported 96.9% 273 
of items.   274 
There was good correlation between the Cochrane and CONSORT scores of individual papers.  275 
There was no relationship found between quality of conduct and reporting of RCTs relevant to 276 
pharmacy and journal impact factor. For example, the journal with the highest impact factor, 277 




both the Cochrane risk of bias tool and the CONSORT checklist than BMC Public Health 279 
(impact factor 0). 280 
  281 
A strength of this review is its novelty and relevance to improving the research evidence base 282 
for pharmacy. It was conducted systematically and reported according to the PRISMA 283 
statement.14 Further, the use of adjusted scores for CONSORT gave a more accurate 284 
representation of quality. This is especially important given that trials in health services 285 
research may not always find every item relevant. Indeed, the issue of blinding can be more 286 
difficult to achieve in this context, than perhaps a more traditional drug trial. Recognising and 287 
acknowledging the implications of the potential biases this introduces is therefore particularly 288 
important.   289 
  290 
There are some limitations to the review. Firstly, the sample size of 50 papers is relatively small, 291 
and therefore the results of this review may not be generalisable to all pharmacy relevant RCTs. 292 
However, the sample is diverse, covering many topics, settings, countries and journals. 293 
 294 
Secondly, only one data base was searched due to time restrictions. However, Medline is one 295 
of the most comprehensive databases for this category of paper and previous systematic reviews 296 
in this field have found that adding in other databases such as Embase and CINAHL do not 297 
greatly increase the number of unique titles for screening. Further, due to lack of time and 298 
resource we did not conduct independent duplicate data extraction and coding.   As a quality 299 
assurance measure, a second researcher extracted and coded data from a random 20% of papers, 300 





Further, it has been assumed that each domain of the Cochrane tool and each item of the 303 
CONSORT checklist are of equal weight. Ideally, a formal consensus, such as a Delphi survey, 304 
would have been conducted to weight the items and domains, and ultimately develop a validated 305 
score.  Finally, the review has focussed on the study setting not the researchers per se. It is 306 
recognised that research teams are heterogeneous in their academic affiliations and individual 307 
disciplines making it hard to tailor the key messages for improvement appropriately. 308 
 309 
The findings of this review have multiple implications for future research. Jull et.al22 conducted 310 
a comparable review in nursing journals. As in this review, it was found that allocation 311 
concealment was the domain of the Cochrane tool least likely to be assessed as low risk of bias 312 
(20.5%).22 The results from Jull et.al’s review in combination with the results of the current 313 
review suggest that evidence from future RCTs in health services (e.g. pharmacy and nursing) 314 
could be more robust if more attention was paid to allocation concealment during the design of 315 
the trial.  316 
 317 
Another similar review carried out with RCTs in anti-arrhythmic drugs by Camm et.al found 318 
that the mean compliance score to the CONSORT checklist was 15.4 out of 25 items, 61.8% 319 
(SD 3.05, range 9-22.5), calculated using similar methods to the current review.23 The review 320 
by Camm et.al revealed relatively low percentages of RCTs were compliant with items 8a, 8b, 321 
9 and 10 of the CONSORT checklist, with scores of 25.4%, 18.6%, 13.6% and 6.8% 322 
respectively.23 Although higher numerically, the results of these items for the current review 323 
are similar, in that they are relatively low. Interestingly, Camm et.al found that there was a 324 
significant correlation (R=0.45, p<0.001) between CONSORT score and journal impact factor, 325 
contrary to the results of the current review. This might be because the current review focussed 326 




pharmacy and medical journals. Camm et.al focussed their review on RCTs involving anti-328 
arrhythmic drugs, which may have been published in higher impact medical journals.  329 
 330 
A review assessing the quality of reporting of RCTs according to CONSORT carried out in 331 
otorhinolaryngologic medicine by Peters et.al 24 found that RCTs reported in general medical 332 
journals had a significantly higher compliance to CONSORT reporting than those published in 333 
ear, nose and throat (ENT) specific journals (p<0.001). These findings were hypothesised to be 334 
due to higher impact general medical journals requesting RCTs to be reported in accordance to 335 
CONSORT. Implications to be drawn from Peters et.al and the current review are that for the 336 
quality of reporting of RCTs to improve, endorsement from journals and research funding 337 
bodies of CONSORT reporting and other recognised guidelines appropriate to other study 338 
designs may be necessary. Lower impact, more specialised journals in areas of health and 339 
medical research, such as pharmacy and otorhinolaryngologic medicine could potentially 340 
increase their impact factor by encouraging reporting according to CONSORT and only 341 
accepting complete and transparent RCT reports. Interestingly, Peters et.al’s findings 342 
additionally supported the results of the current review and the review by Camm et.al, that 343 
items 8a, 8b, 9 and 10 of the CONSORT checklist are inadequately reported in both specialty 344 
ENT journals and general medical journals. 345 
 346 
Overall, conclusions to be drawn from the current review and previous systematic reviews of 347 
the quality of conduct and reporting of RCTs in health services research22-24 include the 348 
requirement for researchers conducting RCTs to focus on including details of randomisation, 349 
sequence generation and allocation concealment (items 8a to 10 of CONSORT). These areas 350 
were found in the current review and in previous reviews to have been inadequately reported in 351 




the sequence generation and allocation concealment domains of the Cochrane tool. 353 
Additionally, it can be concluded that although the current review found no correlation between 354 
journal impact factor and quality of conduct and reporting, this finding was not supported by 355 
the results of previous reviews. Future reviews considering the quality of conduct and reporting 356 
of RCTs relevant to pharmacy should consider ascertaining whether journals in which the RCTs 357 
are published require the use of CONSORT when reporting RCTs, as well as the impact factor 358 
of the journal to identify if there is a correlation between endorsement of CONSORT and 359 
adherence to the recommendations. Future lines of enquiry could also include exploring 360 
associations with other potential predictors of research quality such as funding type (eg 361 
Research Council or commercial or none), or reporting of earlier feasibility and piloting.  362 
Qualitative work could also be conducted to understand the reason for the deficiencies and 363 
introduce interventions to address them. For example, is it lack of expertise and expert advice, 364 
lack of funding and/or lack of time?   365 
CONCLUSION 366 
The results of this review have identified areas of pharmacy related research which are either 367 
not conducted to the highest standard or where the reporting is inadequate, suggesting an aspect 368 
of an RCT was either not completed or reporting made it difficult to judge whether it was 369 
completed well. These are mostly associated with randomisation and blinding.   It therefore 370 
highlights the need for identifying ways in which to update researchers on the standards 371 
expected to allow pharmacy research findings to have the greatest validity and therefore impact. 372 
We especially commend all researchers to access and apply the relevant research guidelines 373 
which exist.   374 
 375 
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Table 1. Inclusion and exclusion criteria 
Inclusion Exclusion 
1. Results of RCT reported 
2. Relevant to pharmacy 
3. Recently published (2015-2017) 
4. English language papers 
5. Available online 
1. Published RCT protocols 
2. Pilot studies 
3. Pharmacokinetic studies 
4. Interventions in which the pharmacist’s only role is blinding 
5. Interventions involving a pharmacy student  
6. Non-English language papers 
7. Papers not available online 
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Table 2. Search terms used to identify records on Medline database. Terms within columns were combined with the Boolean operator 
“OR”, terms across columns were combined with the Boolean operator “AND”. 
The Cochrane highly sensitive search strategy for identifying 
randomised controlled trials in Medline 
Search terms used for identifying RCTs relevant to pharmacy  
1. Randomi?ed controlled trial.pt. 
2. Controlled clinical trial.pt. 
3. Randomi?ed.ab. 
4. Placebo.ab. 




9. 1 OR 2 OR 3 OR 4 OR 5 OR 6 OR 7 OR 8 
10. Animals.mh NOT humans.mh 
11. 9 NOT 10  
1. Pharmacist OR pharmacy OR pharmacists OR 
pharmacies OR pharmacy technician OR chemist 
2. *Pharmacists/ 
3. Pharmacy OR pharmacies OR pharmacist OR pharmacy 
technician.mp [mp = title, abstract, original title, name of 
substance word, subject heading word, keyword heading 
word, protocol supplementary concept word, rare disease 
supplementary concept word, unique identifier, 
synonyms] 





Table 3. Description of papers *  
CONSORT score (%) median (IQR) 59.5 (52.0-70.3) 
Adjusted CONSORT score (%) median (IQR) 72.4 (IQR 61.8-83.9). 
Cochrane score (%) median (IQR) 50.0 (33.3-66.7) 
Continent n (%) 
 
Africa 1 (2) 
Asia 12 (24) 
Australasia 4 (8) 
Europe 12 (24) 
North America 20 (40) 
South America  1 (2) 
Journal n (%) Addiction 2 (4) 
American Journal of Kidney Disease 2 (4) 
Basic and Clinical Pharmacology and Toxicology 1 (2) 
BioMed Research International 1 (2) 
BioMed Central Health Services Research 4 (8) 
BioMed Central Nephrology 1 (2) 
BioMed Central Public Health 1 (2) 
British Journal of Clinical Pharmacy 1 (2) 
The Consultant Pharmacist 1 (2) 
Drug and Alcohol Dependence 1 (2) 
Drugs & Aging 1 (2) 
Health and Quality of Life Outcomes 1 (2) 
Hypertension 1 (2) 
International Journal of Clinical Pharmacy  7 (14) 
International Journal of Cardiology  1 (2) 
Journal of the American Society of Hypertension 2 (4) 
Journal of General Internal Medicine 1 (2) 
Journal of Medical Systems 1 (2) 
Journal of Pharmaceutical Sciences 1 (2) 
Journal of Clinical Pharmacy and Therapeutics 2 (4) 
Journal of Hospital Medicine 1 (2) 
Journal of Managed Care and Specialty Pharmacy 2 (4) 
Journal of Pharmacy Practice 1 (2) 
Journal of the American College of Cardiology 1 (2) 
The Medical Journal of Australia  1 (2) 
Patient Education and Counselling 1 (2) 
The Permanente Journal 1 (2) 
Pharmacotherapy 2 (4) 
PLOS One 1 (2) 
Population Health Management 1 (2) 
Process Evaluation and Measurement 1 (2) 
Research in Social and Administrative Pharmacy 1 (2) 
Telemedicine and e-Health 1 (2) 
The Diabetes Educator 1 (2) 
The Journal of Clinical Hypertension 1 (2) 
Topic of trial n (%) Clinical  25 (50) 


























Hypertension 5 (10) 
CVD*  3 (6) 
Respiratory disease  3 (6) 
CKD** 3 (6) 
Oncology 3 (6) 
Osteoporosis 1 (2) 
Gout 1 (2) 
Iron-overload  1 (2) 
Medication management/use 17 (34) 
Public health  6 (12) 
Smoking cessation 4 (8) 
Sexual health/HIV^ 1 (2) 
Alcohol 1 (2) 
CPD^^ 2 (4) 
*CVD = Cardiovascular disease, **CKD= Chronic kidney disease, ^HIV= Human immunodeficiency virus, ^^CPD = Continuing professional development 
*Data were not normally distributed, therefore median and IQR reported 
Table 4. Number and percentages of papers assessed at different levels of risk  for each domain of the Cochrane tool  




Low risk of bias n 
(%) 
High risk of bias n 
(%) 
Unclear risk of 
bias n (%) 
Sequence generation: 3 23 (46) 25 (50) 2 (4) 
Allocation concealment: 5 16 (32) 32 (64) 2 (4) 
Blinding: 4  20 (40) 28 (56) 2 (4) 
Incomplete outcome data: 2 33 (66) 2 (4) 15 (30) 
Selective outcome reporting: 1 41 (82) 2 (4) 7 (14) 




Table 5. Number and percentage of papers complying with each item on the CONSORT checklist. 
CONSORT checklist item Item 
completion 
rank (/37) 








complete n (%) 
1a: Identification as a randomised trial in the title =24 32 (64) 18 (36) 0 (0) 0 (0) 0 (0) 
1b: Structured summary of trial design, methods, 
results, and conclusions  
19 41 (82) 1 (2) 0 (0) 0 (0) 8 (16) 
2a: Scientific background and explanation of rationale =1 50 (100) 0 (0) 0 (0) 0 (0) 0 (0) 
2b: Specific objectives or hypotheses =5 49 (98) 0 (0) 1 (2) 0 (0) 0 (0) 
3a: Description of trial design (such as parallel, 
factorial) including allocation ratio 
=31 18 (36) 0 (0) 0 (0) 0 (0) 32 (64) 
3b: Important changes to methods after trial 
commencement (such as eligibility criteria), with 
reasons 
=1 3 (100)* 0 (0) 0 (0) 47 (0) 0 (0) 
4a: Eligibility criteria for participants =9 48 (96) 2 (4) 0 (0) 0 (0) 0 (0) 
4b: Settings and locations where the data were 
collected 
=5 49 (98) 1 (2) 0 (0) 0 (0) 0 (0) 
5: The interventions for each group with sufficient 
details to allow replication, including how and when 
they were actually administered 
=11 47 (94) 0 (0) 1 (2) 0 (0) 2 (4) 
6a: Completely defined pre-specified primary and 
secondary outcome measures, including how and 
when they were assessed 
=11 47 (94) 0 (0) 3 (6) 0 (0) 0 (0) 
6b: Any changes to trial outcomes after the trial 
commenced, with reasons 
=1 1 (100)* 0 (0) 0 (0) 49 (0) 0 (0) 
7a: How sample size was determined 27 30 (60) 19 (38) 0 (0) 0 (0) 1 (2) 
7b: When applicable, explanation of any interim 
analyses and stopping guidelines 
36 0 (0) 1 (2) 0 (0) 49 (98) 0 (0) 
8a: Method used to generate the random allocation 
sequence 
28 28 (56) 21 (42) 1 (2) 0 (0) 0 (0) 
8b: Type of randomisation; details of any restriction 
(such as blocking and block size) 
=31 18 (36) 27 (54) 1 (2) 0 (0) 4 (8) 
9: Mechanism used to implement the random 
allocation sequence (such as sequentially numbered 
containers), describing any steps taken to conceal the 
sequence until interventions were assigned 
33 15 (30) 35 (70) 0 (0) 0 (0) 0 (0) 
10: Who generated the random allocation sequence, 
who enrolled participants, and who assigned 
participants to interventions 
30 22 (44) 27 (54) 0 (0) 0 (0) 1 (2) 
11a: If done, who was blinded after assignment to 
interventions (for example, participants, care 
providers, those assessing outcomes) and how 
29 26 (52) 24 (48) 0 (0) 0 (0) 0 (0) 
11b: If relevant, description of the similarity of 
interventions 
=1 8 (100)* 0 (0) 0 (0) 42 (84) 0 (0) 
12a: Statistical methods used to compare groups for 
primary and secondary outcomes 
=5 49 (98) 0 (0) 0 (0) 0 (0) 1 (2) 
12b: Methods for additional analyses, such as 
subgroup analyses and adjusted analyses 
17 30 (85.7)* 4 (8) 1 (2) 15 (30) 0 (0) 
13a: For each group, the numbers of participants who 
were randomly assigned, received intended treatment, 
and were analysed for the primary outcome 
21 40 (80) 8 (16) 0 (0) 0 (0) 2 (4) 
13b: For each group, losses and exclusions after 
randomisation, together with reasons 
26 29 (60.4)* 14 (28) 2 (4) 2 (4) 3 (6) 
14a: Dates defining the periods of recruitment and 
follow-up 




































14b: Why the trial ended or was stopped 35 2 (4)  48 (96) 0 (0) 0 (0) 0 (0) 
15: A table showing baseline demographic and 
clinical characteristics for each group 
=9 48 (96) 2 (4) 0 (0) 0 (0) 0 (0) 
16: For each group, number of participants 
(denominator) included in each analysis and whether 
the analysis was by original assigned groups 
13 46 (92) 1 (2) 3 (6) 0 (0) 0 (0) 
17a: For each primary and secondary outcome, results 
for each group, and the estimated effect size and its 
precision (such as 95% confidence interval) 
18 42 (84) 1 (2) 3 (6) 0 (0) 4 (8) 
17b: For binary outcomes, presentation of both 
absolute and relative effect sizes is recommended 
22 19 (76)* 2 (4) 2 (4) 25 (50) 2 (4) 
18: Results of any other analyses performed, 
including subgroup analyses and adjusted analyses, 
distinguishing pre-specified from exploratory 
20 30 (81.1)* 4 (8) 2 (4)  13 (26) 1 (2) 
19: All important harms or unintended effects in each 
group  
23 2 (66.7)* 0 (0) 0 (0) 47 (94 1 (2) 
20: Trial limitations, addressing sources of potential 
bias, imprecision, and, if relevant, multiplicity of 
analyses 
=5 49 (98) 1 (2) 0 (0) 0 (0) 0 (0) 
21: Generalisability (external validity, applicability) 
of the trial findings 
16  43 (86) 3 (6) 4 (8) 0 (0) 0 (0) 
22: Interpretation consistent with results, balancing 
benefits and harms, and considering other relevant 
evidence 
=5 49 (98) 0 (0) 0 (0) 0 (0) 1 (2) 
23: Registration number and name of trial registry =24 32 (64) 0 (0) 0 (0) 0 (0) 18 (36) 
24: Where the full trial protocol can be accessed, if 
available 
34 6 (12) 41 (82) 0 (0) 0 (0) 3 (6) 
25: Sources of funding and other support (such as 
supply of drugs), role of funders 
14 45 (90) 4 (8) 0 (0) 0 (0) 1 (2) 











Figure 1: Inclusion process for records identified through database searching. Of the 57 eligible full texts, the most recent 50 
records were included. 
Most recently published papers screened by 
title:  
n= 200 
Records identified through database 
searching (Medline): 
n=1517 
Records excluded (N= 27)  
Feasibility/pilot study: n= 25 
Pharmacokinetic studies: n= 1 
Studies involving pharmacy students: n=1 
 
Records remaining after removal of duplicate 
papers:  
n= 150 
Records remaining to be screened by 
abstract:  
n= 123 
Records kept for full text analysis:  
n= 57 
Records excluded (N= 66)  
Pharmacist only role is blinding: n= 17 
No involvement of pharmacy/pharmacist: n= 26 
Studies involving pharmacy students: n=5 
Study design not an RCT: n=8 
Feasibility/pilot study: n= 5 




































Records excluded (N =2) 
Results of RCT not reported:  
n= 1 
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Figure 2. Panel A shows the correlation between Cochrane and CONSORT scores of individual papers. Panel B shows 
correlation between Cochrane and adjusted CONSORT of individual papers. NOTE: there are fewer data points than 
papers, as some data points represent more than one paper. 
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Figure 3. The relationship between journal impact factor and median CONSORT, median adjusted CONSORT and median Cochrane 
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Supplemental material 1 . Summary of article characteristics and findings 
Article ID Author, year Country Aims/objectives Methods Findings  
1.  Treibich, 201725 France Identify benefits of dispensing exact pill 
numbers 
Experimental group counted out medication by unit, 
control group received existing pharmaceutical 
company box sizes 
Beneficial to environment (less wasted), medication 
adherence and public health to dispense exact number of 
pills. 
2.   Lalonde, 201726  Canada Assess impact of ProFiL program on 
medication adherence in patients with 
CKD 
Intervention group pharmacists received 90-minute 
web-based training program about medication use in 
CKD, control group - usual care 
ProFiL trained pharmacists lead to fewer drug related 
problems in patients with CKD 
3.  Tong, 201727  Australia Determine if pharmacist-completed 
medication management plans reduce rate 
of medication errors in discharge 
summaries 
Intervention group received pharmacist medication 
management plans, control group standard medical 
discharge summaries 
Significant reduction in medication errors in medication 
management plans completed by pharmacists 
4.  Periasamy, 
201728 
Malaysia Develop, implement and evaluate 
pharmacist led chemotherapy counselling 
on quality of life 
Intervention group received counselling “Managing 
patients on chemotherapy” from pharmacist. 
Managing patients on chemotherapy and repetitive 
counselling from pharmacists was shown to increase 
quality of life in oncology patients 
5.  Manfrin, 201718 UK Evaluate the Italian Medicines Use review 
(I-MUR) using asthma patients 
Structured, face-to-face asthma education from 
pharmacist  
I-MUR demonstrated effectiveness and cost-effectiveness 
6.  Houle, 201729 Canada Explore the needs of community 
pharmacies to provide medication 
management services  
Intervention pharmacies received external task-
focused facilitation, control group usual practice 
External facilitation seems to be feasible and acceptable to 
support community pharmacy medication management 
services 
7.  El Hajj, 201719 Qatar Test the effect of a structured face-to-face 
pharmacist intervention to aid smoking 
cessation 
Intervention group received structured support from 
pharmacist at 2-4 week intervals, control group 
received brief unstructured smoking cessation advice 
There was no statistically significant difference in 
smoking abstinence rates at 12 months between groups 
8.  Bahnasawy, 
201630 
Egypt Evaluate the occurrence of drug related 
problems in paediatric beta-thalassaemia 
major patients 
Control group received standard medical care, 
intervention group received standard medical care 
plus clinical pharmacy services 
There was a decline in the number of drug related 
problems in the intervention group from baseline to follow 
up 
9.  Axtell, 201731 USA To compare the effectiveness of 4 
different instructional interventions in 
correct inhaler technique 
Subjects assigned to one of four interventions: 1. 
Read MDI instructions, 2. Watch CDC video 
demonstrating MDI technique, 3. Watch a youtube 
video demonstrating MDI technique, 4. Receive direct 
instruction of MDI technique from pharmacist. 
A 2-minute pharmacist counselling session is more 
effective than other interventions in correctly teaching 
inhaler technique. 
10.  Kane-Gill, 201632 USA Assess the importance and performance of 
consultant pharmacist services to detect 
and manage adverse drug events (ADEs) 
among nursing home residents 
Clinical pharmacy services including academic 
detailing to physicians, response to drug alerts, and 
provision of structured recommendations about ADE 
management were provided in the intervention 
Clinical pharmacy led intervention can improve 
physician’s assessment of importance and performance of 
clinical pharmacy services 
11.  Gong, 201633 USA To evaluate enhance pharmacy care 
program of pharmacist telephone 
counselling for smoking cessation  
Intervention group patients received 3 telephone 
counselling sessions from specialist pharmacists, 
control group received usual care 
Pharmacist telephone counselling to encourage smoking 





12.  Spoelstra, 201634 USA Evaluate the acceptability of Text 
message support in adult cancer patients 
Intervention patients received text messages 
according to their medication regimen, control group 
received usual care 
Adult cancer patients were likely to enrol into text 
message support  
13.  Anderegg, 201635 USA Evaluate if pharmacist intervention can 
minimise healthcare disparities in high-
risk racial and socioeconomic 
hypertensive patients 
Patients in intervention group received structured 
interview with pharmacist, control group received 
usual care 
Pharmacist intervention reduced racial and socioeconomic 
disparities in the treatment of hypertension 
14.   Qudah, 201636 Jordan Evaluate the clinical pharmacist’s role in 
the management of blood pressure in 
haemodialysis patients 
Intervention arm patients received physician-
pharmacist collaborative care, control group received 
standard medical care 
Collaborative pharmacist-physician care improved rate of 
blood pressure control in haemodialysis patients 
15.  Malet-Larrea, 
201637 
Spain Assess impact of medication review with 
follow up provided in community 
pharmacy to aged polypharmacy patients 
on the number of medication related 
hospital admissions 
Intervention group pharmacies provided 
comprehensive medication review, control group 
delivered usual care 
Medication review and follow up delivered by community 
pharmacists might be effective in reducing medication 
related admissions 
16.  Tong, 201638 Australia Evaluate the effectiveness of a partnered 
pharmacist charting model completed at 
the time of admission to reduce 
medication errors 
Intervention patients received partnered pharmacist 
charting, control group received standard medical care 
Partnering between medical staff and pharmacists to 
jointly chart initial medications on admission significantly 
reduced inpatient medication errors 
17.  Messerli, 201639 Switzerland Investigating the impact of 
Polymedication check (PMC) on 
polypharmacy patients 
Intervention group received a PMC at baseline and 
after 28 weeks, control group only received PMC at 
28 weeks. 
Through the PMC the pharmacist was able to identify a 
significant number of Drug related problems 
18.  Geurts, 201640 The 
Netherlands 
To determine whether a clinical 
medication review followed by a 
pharmaceutical care plan reduces the 
number of potential drug related problems 
and pharmaceutical care issues 
Intervention patients received a clinical medication 
review, followed by development of a pharmaceutical 
care plan. Control group received care as usual 
The integrated use of clinical medication review and 
pharmaceutical care plan development facilitates the 
detection of and decrease in drug related problems 
19.  Smith, 201641 USA Compare physician-pharmacist 
collaborative model to usual hypertension 
care 
Intervention group received collaborative physician-
pharmacist care, control group received usual 
hypertension care 
Team based care in the primary care setting may be 
effective at treating treatment resistant hypertension  
20.  Tsuyuki, 201642 Canada Evaluate the effectiveness of a community 
pharmacy-based case finding and 
intervention on cardiovascular risk 
Usual care group received usual pharmacist care, 
intervention group received medication therapy 
management review from their pharmacist and CVD 
risk assessment and education 
The results demonstrated a significant reduction in risk for 
CVD events in intervention patients 
21.  Basheti, 201643 Jordan Identificaiton of treatment related 
problems through a medication 
management review  
All patients visited in their home for medication 
management review, pharmacist sent letter to GP of 
intervention group patients with receommendations 
regarding treatment 
Home based medication management review decreased the 
total number of treatment related probelsm and improved 
self-reported adherence  
22.  Lim, 201644 Malaysia Assess the clinical outcomes of patients 
managed by pharmacists in Diabetes 
Medication Therapy Adherence Clinic 
(DTMAC) 
Intervention group received usual care plus DTMAC, 
including 8 follow up visits. Control group received 
usual care 
Pharmacist managed DTMAC significantly improved 
glycaemic control and lipid profile of diabetic patients 
23.  Bell, 201645 USA Determine the effect of a tailored, 
pharmacist-delivered health literacy 
intervention on unplanned healthcare 
utilisation 
Intervention group received pharmacist assisted 
medication reconciliation, inpatient pharmacist 
counselling, adherence aids and individualised 
telephone follow up after discharge 





24.  Goldfien, 201646 USA To determine whether a pharmacist 
staffed gout management program is more 
effective in achieving target serum uric 
acid levels in gout patients 
Intervention group received management by a clinical 
pharmacist following protocol, control group received 
management of their gout from their usual treating 
physician 
A structured pharmacist staffed program was more 
effective than usual care for achieving target serum uric 
acid levels 




To determine if having a group of users 
perform a similar task over a prolonged 
period of time leads to improvements in 
efficiency in that task 
Independent physician-pharmacist teams conducted 
medication reviews using supported software 
The amount of time users needed to perform similar tasks 
decreased significantly as they gained experience over 
time 
26.  Phatak, 201648 USA Assess the impact of pharmacist 
involvement in transitions of care 
measured by decreased medication errors 
The control group received standard hospital care. 
The intervention group received face-to-face 
medication reconciliation, patient specific 
pharmaceutical care plan, discharge counselling and 3 
post-discharge phonecalls 
It was demonstrated that pharmacist involvement in 
hospital discharge transitions of care had a positive impact 
on decreasing inpatient readmissions and ED visits 
27.  Basheti, 201649 Jordan To assess the impact of a medication 
management review service on treatment 
related problems and certain clinical 
outcomes in outpatients 
The clinical pharmacist conducted baseline 
assessment in both patient groups, reccomendations 
regarding treatment related problems were only 
forwarded to the physician of intervention group 
patients 
The medication management review service resulted in 
significantly lower number of treatment related problems 
and improved clincial outcomes 
28.  Blackburn, 
201616 
Canada To test a brief intervention for preventing 
statin nonadherence among community 
pharmacy patrons 
Intervention pharmacists attended a 2.5 hour training 
addressing barriers to statin adherence and screened 
for new statin users to assess their compliance 
The intervention was ineffective for improving patient 
adherence to statin therapies in community pharmacies 
29.  Ishani, 201650 USA To determine whether an intervention 
consisting of telehealth with 
interprofessional team case management 
could be effectively implemented and 
improve the combined end point of death, 
hospitalisation, ED visits or admission to 
nursing home in patients with CKD 
Intervention patients received care from an 
interprofessional team using a telehealth device, 
control patients received usual care 
Telehealth by an interprofessional team is a feasible care 
delivery strategy in patients with CKD. There was no 
statistically significant evidence of the interventions 
superiority on health outcomes over usual care 
30.  Roblek, 201651 Slovenia To determine if interventions by clinical 
pharmacists can reduce the prevalence of 
clinically relevant drug drug interactions 
during hospitalisation of patients with 
heart failure 
All attending physicians received standard advice 
about pharmacologic therapy, those in the 
intervention group also received alerts about clinically 
relevant DDIs 
Pharmacist intervention significantly reduces the number 
of patietns with clinically relevant DDIs, but not clinical 
endpoints 6 months from discharge 
31.  Suhaj, 201652 India Evaluate the effectiveness of clinical 
pharmacist intervention on health related 
quality of life (HRQoL) in patients with 
COPD 
The intervention pharmacist emphasised importance 
of medication compliance, smoking cessation, simple 
ecercise, proper use of inhalers, need for timely 
follow up. Control group received usual care 
Pharmacist intervention improved HRQoL of patients with 
COPD. 
32.  O’Sullivan, 
201653 
Ireland To design a structured pharmacist review 
of medications supported by software for 
reducing adverse drug reactions in older 
hospitalised patients 
Intervention patients received the clinical decision 
software supported structured pharmacist review of 
medications within 48h of admission, control group 
received care as usual 
The intervention significantly reduced incidence of 
adverse drug reactions in acutely hospitalised older people 
33.  Thomas, 201654 Australia Evaluate the effectiveness of a 
pharmacist-led multi-component smoking 
cessation program  
Pharmacist-led behavioural counselling and/or 
pharmacotherapy provided during hospital stay, on 
discharge and one month post discharge was provided 
to the intervention group, control group received 
routine hospital care 
The intervention did not improve sustained abstinence 




34.  Chen, 201655 Taiwan To evaluate the effects of pharmaceutical 
care on glycaemic control of ambulatory 
older patients with type 2 diabetes  
Control group received standard care, intervention 
group received pharmaceutical care from a certified 
diabetes educator pharmacist who identified and 
resolved drug related problems  
The intervention improved long-term safe control of blood 
sugar levels for ambulatory older adults with type 2 
diabetes  
35.  Wang, 201521 China Evaluate the efficacy of pharmaceutical 
intervention on chemotherapy knowledge, 
attitude and practice (KAP) and quality of 
life (QoL) in cancer patients 
Intervention group patients were given information 
booklets and 30 minute face-to-face medication 
education and psychological counselling by clinical 
pharmacists twice weekly for 2 months 
The intervention significantly improved KAP and QoL in 
adult cancer patietns over control. 
37. 
 
Dhital, 201520 UK To evaluate the effectiveness of a brief 
intervention delivered by community 
pharmacists to reduce hazardous or 
harmful drinking 
Control group patients received a leaflet about the 
harms of drinking, intervention group patients 
received a brief motivational discussion (10mins) 
from a pharmacist who had received a half-day 
training in delivering the intervention  
The brief motivation discussion appeared to have no effect 
in reducing hazardous or harmful alcohol consumption  
38. 
 
Donyai, 201556 UK Test the outcome of training people to use  
CPD framework through distance learning 
material 
The control group received information in the mail 
about new CPD requirements, the intervention group 
received the CPD framework and associated training 
The intervention was shown to improve participant’s CPD 
behaviour 
39. Tso, 201557 USA Evaluate the impact of conducting a 
pharmacist-led telephone outreach 
program to improve osteoporosis 
managemnet in elderly women after 
experiencing fractures 
The patients were split into 3 groups: baseline 
intervention consisting of patient education mailing, 
baseline intervention plus a live outbound 
intervention call to patients by pharmacist, and 
baseline intervention plus pharmacist call to patients 
health providers to recommend initiation of 
osteoporosis therapy and/or BMD test  
Pharmacist calls did not improve osteoporosis 
management over mail and fax notifications 
40. Basger, 201558 Australia Examine the effects of applying a 
validated  prescribing appropriateness 
criteria set during medication review in 
patients >65 at time of discharge from 
hospital 
Control group patients received usual care, 
intervention received discharge medication 
counselling and review from a clinical pharmacist 
The intervention did not increase the number of 




Germany Evaluate the impact of pharmaceutical 
care in adolescents with T1DM provided 
by pharmacists in collaboration with 
physicians on important clinical outcomes 
Intervention group received structured monthly 
pharmaceutical care visits plus supplementary visits 
as needed for 6 months, control group received usual 
diabetic care 
The findings suggest that multi-disciplinary 
pharmacuetical management may add value in adolescent 
patients with T1DM 
43. Carter, 201560 USA To evaluate the sustained hypertension 
control following pharmacist intervention 
in veterans 
All patients received intensive pharmacist 
intervention for the first 6 months, at which point the 
patients were stratified based on BP control and 
randomised to continue the intervention for 24 months 
or cease the intervention 
The findings suggest that once BP control is achieved 
following pharmacist intervenion patients can be referred 
back to their primary care provider 
44. Kooy, 201561 The 
Netherlands 
Assess effects of pharmacists’ counselling 
by telephone on patients satisfaction with 
counselling and information and beliefs 
about medicines for newly prescribed 
medicines 
Control patients received usual care, intervention 
patients received telephone counselling to address 
barriers to adherent behaviour 
Telephone counselling by pharmacists improved 




Iran Investigate the efficacy of a community-
pharmacist delivered diabetes support 
program for patients receiving specialty 
medical care 
The pharmacist trained patietns in the intervention 
group for 5 months including 5 follow up visits and 5 
phone calls. Control group received care as usual 
The intervention improved self-care activity, medication 




Malaysia Determine the baseline satisfaction level 
of newly diagnosed diabetics and to 
Intervention group received pharmaceutical care, 
control group patients received usual care from 
The intervention significantly improved the satisfaction 




explore the impact of pharmaceutical care 
intervention on patient’s satisfaction 
during their follow ups 
physicians/nurses. Outcomes measuresd at baseline, 
3, 6, 9 and 12 months. 
47. Cooney, 201563 USA To evaluate the effect of a pharmacist 
based quality improvement program on 
outcomes for patients with CKD and 
adherence to CKD guidelines in primary 
care setting 
Intervention patients received a phone-based 
pharmacist intervention, pharmacist-physician 
collaboration and patient education  
The intervention did not improve BP control in patients 
with CKD, however it did improve guideline adherence 
48. Adams, 201564 USA To determine whether brief, structured 
telephonic tobacco cessation counselling 
delivered by clinical pharmacists 
impacted tobacco cessation attempts 
compared to usual care 
Control group received usual care, the intervention 
group received brief, structured telephone tobacco 
cessation counselling 
It was found that the brief structured telephone 
intervention may not adequately affect patient motivation 
to impact tobacco cessation attempts 
49. Javadi, 201565 Iran Compare the efficacy of two types of 
continuing pharmacy education on 
selected reproductive health topics 
Intervention group received small group training with 
simulated patients, while control group received the 
CPE in didactic lecture format 
There were no significant differences observed between 
satisfaction and attitude scores of the two groups 
50. Gums, 201566 USA To describe medication adherence and 
medication intensification in a physician-
pharmacist collaborative management 
(PPCM) model compared to usual care 
Control group received usual care, intervention group 
received a structured pharmacist interview and 
created a care plan 
The PPCM model increased medication intensification, 
however no significant change in medication adherence 
was detected 
51. Lewis, 201567  USA To examine the impact of a pharmacy-
randomised intervention to reduce 
injection risk amongst people who inject 
drugs  
Intervention pharmacies received in depth harm 
reduction training and recurited syringe customers 
into the study and provided additional services, 
primary control pharmacies recruited syringe 
customers into the study but did not provide 
additional services, secondary control did not recruit 
The findings suggest that expanded pharmacy services for 
people who inject drugs can ecnourage sterile syringe use 
and decrease injection risk  
52. Becerra-
Camargo, 201568 
Colombia To measure the impact of pharmacist-
acquired medication history during 
admission to an ED 
All patients had standardised, comprehensive 
medication history interview focusing on the patient’s 
current home medication regimen prior to being seen 
by the Dr 
It was found that involving a pharmacist and drawing up a 
history of complete medicaiton could contribute towards 
reducing the risk of potential adverse drug events  
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